Valsartan News - N-nitrosodimethylamine (NDMA) Contamination

Below are some of our news stories explaining the dangers of Valsartan contaminating with N-nitrosodimethylamine (NDMA). To learn about the legal claims that have been filed, click Valsartan.

  • Yet Another Sartan Drug Recalled Due to Carcinogens

    Aurobindo Pharma USA, Inc. has issued a voluntary recall of three of its sartan-based prescription medications after discovering trace amounts of a carcinogenic substance known as N-nitrosodiethylamine (NDEA). The recall, which the FDA announced on Dec. 31st, affects a total of 80 lots of Valsartan, Amlodipine Valsartan, and Valsartan HCTZ pills with expiration dates between May 2019 and March 2021.

    read more
  • A Third Sartan Drug is Found to Contain NDEA

    For the second time in as many weeks, the Food and Drug Administration has notified physicians and patients that yet another sartan drug used to treat hypertension has been contaminated with a carcinogenic industrial chemical. The manufacturer of the drug has issued a voluntary recall for a single lot of the medication losartan (potassium hydrochlorothiazide), identified as JB8912.

    read more
  • Hidden Carcinogen in Common Blood Pressure Medications Casts More Doubts Over China's Drug Industry

    Last month, the China-based Zhejiang Huahai Pharmaceutical Company informed the European Medicines Agency that one of their products used in the treatment of hypertension, known as valsartan, had been contaminated with a chemical known as N-nitrosodimethylamine (NDMA). This substance is a known carcinogen that is used by researchers to intentionally produce cancer in laboratory rats. 

    read more